主页 > 医药生命 >
【medical-news】奈西立肽有望成为冠脉搭桥术中用
21 December 2006
Treating patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) with nesiritide improves postoperative renal function and may increase survival, results of the Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery (NAPA) trial indicate.
Patients who received nesiritide during surgery had better overall preservation of glomerular filtration rate (GFR), lower peak increase in serum creatinine (SCr) levels, and greater urine output in the immediate postoperative period compared with patients receiving placebo, Robert Mentzer (Wayne State University School of Medicine, Detroit, Michigan, USA) and colleagues report.
In addition, nesiritide treatment was associated with reduced hospital stays and decreased mortality at 180 days.
Myocardial revascularization outcomes are adversely affected by both chronic and acute renal insufficiency, and while several therapeutic strategies for preserving renal function after cardiac surgery have been investigated, none has so far proven effective, Mentzer and team say.
For the NAPA trial, the researchers randomly assigned 303 patients undergoing CABG with anticipated cardiopulmonary bypass to either nesiritide 0.01 µg/kg/min without bolus, or placebo, in addition to usual care, for 24 to 96 hours after the induction of anesthesia.
Those who received the study drug had a significantly attenuated peak increase in SCr, at 0.15 versus 0.34 mg/dl (p<0.001), a smaller decrease in GFR during hospital stay, or by day 14, at 10.8 versus 17.2 ml/min/1.73 m2 (p=0.001), and a greater urine output, at 2926 versus 2350 ml (p<0.001).
Nesiritide-treated patients also had a significantly shorter average hospital length of stay (p=0.043) and lower 180-day mortality (p=0.046).
The team concludes that, although the most likely explanation for nesiritide's effects are prevention or attenuation of postoperative renal dysfunction, "additional studies are needed to confirm these findings."
J Am Coll Cardiol 2007; Advance online publication
http://www.incirculation.net/NewsItem/Nesiritide-has-promising-effects-in-CABG.aspx 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 Nesiritide has promising effects in CABG
奈西立肽有望成为冠脉搭桥术中用药
21 December 2006
2006年12月21号
Treating patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) with nesiritide improves postoperative renal function and may increase survival, results of the Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery (NAPA) trial indicate.
对心外科手术中围麻醉期使用普鲁卡因酰胺的患者给予奈西立肽的研究表明，对左心室功能紊乱患者进行冠脉搭桥术时，使用奈西立肽可增强术后肾脏功能，而且或许还能提高存活率。
Patients who received nesiritide during surgery had better overall preservation of glomerular filtration rate (GFR), lower peak increase in serum creatinine (SCr) levels, and greater urine output in the immediate postoperative period compared with patients receiving placebo, Robert Mentzer (Wayne State University School of Medicine, Detroit, Michigan, USA) and colleagues report.
来自美国密歇根州底特律市Wayne州立大学药学院 Robert Mentzer和同事们报道，和服用安慰剂的患者相比，在手术中使用奈西立肽的病人术后对肾小球滤过率、血清肌酸酐水平的降低及排尿量的增多都有较好的全面保护作用。
In addition, nesiritide treatment was associated with reduced hospital stays and decreased mortality at 180 days.
而且，采用奈西立肽治疗可缩减患者住院期以及降低半年内死亡率。
Myocardial revascularization outcomes are adversely affected by both chronic and acute renal insufficiency, and while several therapeutic strategies for preserving renal function after cardiac surgery have been investigated, none has so far proven effective, Mentzer and team say.
Mentzer和他的团队介绍说，在心肌血管重建术后常会出现急慢性肾功能不全，而且各种用于保护心外科手术后肾功能的治疗方案都研究过，到目前为止没有一个是有效的。
For the NAPA trial, the researchers randomly assigned 303 patients undergoing CABG with anticipated cardiopulmonary bypass to either nesiritide 0.01 μg/kg/min without bolus, or placebo, in addition to usual care, for 24 to 96 hours after the induction of anesthesia.
对使用N-乙酰普鲁卡因酰胺的手术进行研究，研究者将303例接受体外循环冠脉搭桥术患者随机分为两组，在麻醉诱导之后24至96小时内，除了常规护理之外，一组给予0.01μg/kg/min的奈西立肽，另一组给予同剂量的安慰剂。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-07 18:33
医学,生命科学网